Oral Immunotherapy Combined With Humanized Monoclonal Anti-IgE Antibody Xolair® (Omalizumab)in the Treatment of Cow's Milk Allergy

Trial Profile

Oral Immunotherapy Combined With Humanized Monoclonal Anti-IgE Antibody Xolair® (Omalizumab)in the Treatment of Cow's Milk Allergy

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Milk hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Results of a biomarker analysis published in the Journal of Allergy and Clinical Immunology.
    • 24 Nov 2015 New trial record
    • 30 Oct 2015 Status changed from active, no longer recruiting to completed, as per an article published in the Journal of Allergy and Clinical Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top